Department of Surgery, National Defense Medical College, Saitama, Japan.
Department of Surgery, National Defense Medical College, Saitama, Japan
In Vivo. 2020 Jul-Aug;34(4):1941-1949. doi: 10.21873/invivo.11991.
BACKGROUND/AIM: In recent years, platelet-related markers were recognized as useful prognostic factors in various malignancies. We investigated the relationship between platelet-related prognostic markers and anti-platelet or anti-coagulant therapies for survival outcomes in esophageal squamous cell carcinoma.
Preoperative platelet-related prognostic markers were evaluated from peripheral blood testing and statistical analyses were performed to evaluate the prognostic value of these markers and reveal the effects of antiplatelets and/or anticoagulants regarding their prognostic relevance.
In all 176 patients, preoperative platelet-to-lymphocyte ratio (PLR) was not found to be a predictor of overall survival (OS). However, in patients without antiplatelet or anticoagulant therapies, PLR was significantly associated with a poor OS (p=0.03). Although platelet large cell ratio (P-LCR) was not associated with the prognosis in patients with antiplatelet and/or anticoagulant therapies, higher P-LCR was associated with a poor prognosis in patients without antiplatelet or anticoagulant therapies (p<0.0001).
Researching detailed antiplatelet and anticoagulant therapies could reinforce the prognostic value of platelet-related prognostic markers in ESCC.
背景/目的：近年来，血小板相关标志物已被认为是各种恶性肿瘤的有用预后因素。我们研究了血小板相关预后标志物与抗血小板或抗凝治疗对食管鳞状细胞癌生存结果的关系。
从外周血检测中评估了术前血小板相关预后标志物，并进行了统计分析，以评估这些标志物的预后价值，并揭示抗血小板和/或抗凝剂对其预后相关性的影响。
在所有 176 名患者中，术前血小板与淋巴细胞比值（PLR）未被发现是总生存期（OS）的预测因素。然而，在未接受抗血小板或抗凝治疗的患者中，PLR 与较差的 OS 显著相关（p=0.03）。尽管血小板大细胞比（P-LCR）与接受抗血小板和/或抗凝治疗的患者的预后无关，但在未接受抗血小板或抗凝治疗的患者中，较高的 P-LCR 与较差的预后相关（p<0.0001）。
研究详细的抗血小板和抗凝治疗可以增强血小板相关预后标志物在 ESCC 中的预后价值。
